Tagrisso does not meet the criteria set up by NICE’s to be considered as a life-extending treatment.
Data suggest that patients who take Tagrisso live longer than their peers who receive Roche’s Tarceva (erlotinib) or AstraZeneca’s own Iressa (gefitinib). However, AstraZeneca was not able to share any information from a randomized clinical trial comparing Tagrisso to Boehringer Ingelheim’s Gilotrif (afatinib) which is the first choice, EGFR tyrosine kinase inhibitor and this may prove to be more effective than the products used in the Tagrisso clinical trials.
AstraZeneca’s efforts to grow sales of Tagrisso is facing a huge challenge but rising demand in market mean the drug is still well positioned. Tagrisso sales in 2019 came in at $2.3bn in about first nine months, up more than 80% over the same period of the 2018.
For more information, please contact bbanik@pharmintel.co.in
Leave a Reply